Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

7.5K
The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

2.5K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Pathomorphological Features of Lung Damage Caused by Infection with Various Variants of SARS-CoV-2 in Humanized Model Animals.

Doklady. Biochemistry and biophysics·2026
Same author

Isolation, Purification, and Structural-Functional Analysis of Recombinant Human Transferrin Produced by the Methylotrophic Yeast Strain Pichia pastoris.

Bulletin of experimental biology and medicine·2026
Same author

The Impact of the Intracellular Domains of Chimeric Antigenic Receptors on the Properties of CAR T-cells.

Acta naturae·2025
Same author

Heterologous Production of Antimicrobial Peptides in Yeast Allows for Massive Assessment of the Activity of DNA-Encoded Antimicrobials In Situ.

Acta naturae·2025
Same author

Detection and Quantification of Polymorphic MICA and MICB Molecules in Immunoassays: Initial Insights.

HLA·2025
Same author

Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.

Sovremennye tekhnologii v meditsine·2025

Video Experimental Relacionado

Updated: Sep 9, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.0K

Matriz específica sobre la base de la enzima convertidora de angiotensina 2: desarrollo y análisis funcional

N N Kostin1, T V Bobik2, N Yu Rushkevich1

  • 1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Bulletin of experimental biology and medicine
|August 28, 2025
PubMed
Resumen

Los investigadores desarrollaron una matriz de afinidad utilizando la enzima convertidora de angiotensina humana 2 (ACE2) para capturar el SARS-CoV-2. Esta innovación es prometedora para reducir la carga viral en pacientes severos de COVID-19 a través de la hemoperfusión extracorpórea.

Palabras clave:
COVID-19; hemoperfusión extracorpórea; ACE2

Más Videos Relacionados

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

37.9K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

5.8K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.0K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

37.9K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

5.8K

Área de la Ciencia:

  • Biotecnología
  • Virología
  • Ciencias de los materiales

Sus antecedentes:

  • El COVID-19 severo se caracteriza por altas cargas virales.
  • Los tratamientos actuales para el COVID-19 grave tienen limitaciones.
  • La hemoperfusión extracorpórea es un método potencial para la purificación de la sangre.

Objetivo del estudio:

  • Desarrollar y caracterizar una nueva matriz de afinidad para la captura del SARS-CoV-2.
  • Para evaluar la eficiencia de unión de la matriz para las partículas virales.
  • Para explorar el potencial de esta matriz para aplicaciones terapéuticas en COVID-19.

Principales métodos:

  • Inmovilización de la enzima recombinante de conversión de la angiotensina humana 2 (ACE2) en un sustrato polimérico poroso.
  • Caracterización de la matriz de afinidad desarrollada.
  • Prueba de la capacidad de unión de la matriz utilizando partículas virales pseudotipadas con la proteína del pico del SARS-CoV-2.

Principales resultados:

  • Se desarrolló con éxito una matriz de afinidad funcional.
  • La matriz demostró una unión eficiente de las partículas virales pseudotipadas del SARS-CoV-2.
  • El ACE2 inmovilizado mantuvo sus propiedades de unión en el sustrato.

Conclusiones:

  • La matriz de afinidad basada en ACE2 desarrollada es una herramienta prometedora para capturar el SARS-CoV-2.
  • Esta tecnología tiene potencial para la hemoperfusión extracorpórea para reducir la carga viral en casos graves de COVID-19.
  • Se necesita más investigación para traducir este hallazgo en la práctica clínica.